SGC-SMARCA-BRDVIII

| Cat. No.: | HY-145446 | | | |
|--------------------|--------------------------|-------|----------|--|
| CAS No.: | 1997319-84-2 | | | |
| Molecular Formula: | $C_{19}H_{25}N_5O_3$ | | | |
| Molecular Weight: | 371.43 | | | |
| Target: | Epigenetic Reader Domain | | | |
| Pathway: | Epigenetics | 5 | | |
| Storage: | Powder | -20°C | 3 years | |
| | | 4°C | 2 years | |
| | In solvent | -80°C | 6 months | |
| | | -20°C | 1 month | |

SOLVENT & SOLUBILITY

| In Vitro | DMSO : 25 mg/mL (67 | DMSO : 25 mg/mL (67.31 mM; Need ultrasonic) | | | | | |
|----------|---|---|-----------|------------|------------|--|--|
| | Preparing Stock Solutions | Solvent Mass Concentration | 1 mg | 5 mg | 10 mg | | |
| | | 1 mM | 2.6923 mL | 13.4615 mL | 26.9230 mL | | |
| | | 5 mM | 0.5385 mL | 2.6923 mL | 5.3846 mL | | |
| | 10 mM | 0.2692 mL | 1.3461 mL | 2.6923 mL | | | |
| | Please refer to the solubility information to select the appropriate solvent. | | | | | | |
| In Vivo | 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution | | | | | | |
| | 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution | | | | | | |
| | 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution | | | | | | |

| Description | SGC-SMARCA-BRDVIII is a potent and selective inhibitor of SMARCA2/4 and PB1(5), with K _d s of 35 nM, 36 nM, and 13 nM, respectively. SGC-SMARCA-BRDVIII also inhibits PB1(2) and PB1(3), with K _d s of 3.7 and 2.0 μM, respectively. SGC-SMARCA-BRDVIII can block adipogenesis of 3T3-L1 murine fibroblasts ^{[1][2]} . | | | |
|---------------------------|---|--|--|--|
| IC ₅₀ & Target | Kd: 35 nM (SMARCA2), 36 nM (SMARCA4), 13 nM (PB1(5)) ^[1] | | | |
| In Vitro | SGC-SMARCA-BRDVIII (compound 22) (1 μ M; 14 days) blocks adipocyte differentiation in 3T3-L1 murine fibroblasts ^[1] . | | | |

Product Data Sheet

.OH

N_{SN}

N

 NH_2



MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Wanior M, et, al. Pan-SMARCA/PB1 Bromodomain Inhibitors and Their Role in Regulating Adipogenesis. J Med Chem. 2020 Dec 10;63(23):14680-14699.

[2]. Mélin L, et, al. Design and Synthesis of LM146, a Potent Inhibitor of PB1 with an Improved Selectivity Profile over SMARCA2. ACS Omega. 2021 Aug 9;6(33):21327-21338.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA